Epidemiological profiles and associated risk factors of SARS-CoV-2 positive patients based on a high-throughput testing facility in India.
COVID-19
India
clinical profile
risk factors
Journal
Open biology
ISSN: 2046-2441
Titre abrégé: Open Biol
Pays: England
ID NLM: 101580419
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
entrez:
1
6
2021
pubmed:
2
6
2021
medline:
11
6
2021
Statut:
ppublish
Résumé
We describe the epidemiological characteristics and associated risk factors of those presenting at a large testing centre for SARS-CoV-2 infection. This is a retrospective record review of individuals who underwent SARS-CoV-2 testing by reverse transcription-polymerase chain reaction (RT-PCR) at a high-throughput national-level government facility located in the north of India. Samples collected from 6 April to 31 December 2020 are included in this work and represent four highly populous regions. Additionally, there was a prospective follow-up of 1729 cases through telephone interviews from 25 May 2020 to 20 June 2020. Descriptive analysis has been performed for profiling clinic-epidemiological aspects of suspect cases. Multivariable logistic regression analysis was undertaken to determine risk factors that are associated with SARS-CoV-2 test positivity and symptom status. A total of 125 600 participants' details have been included in this report. The mean (s.d.) age of the participants was 33.1 (±15.3) years and 66% were male. Among these tested, 9515 (7.6%) were positive for COVID-19. A large proportion of positive cases were asymptomatic. In symptomatic positive cases, the commonest symptoms were cough and fever. Increasing age (groups 20-59 and ≥60 years compared to age group less than 5 years), male sex, history of international travel, symptoms for SARS-CoV-2, and participants from Delhi and Madhya Pradesh were positively associated with SARS-CoV-2 test positivity. Having co-morbidity, risk behaviours and intra-familial positivity were associated with a positive odds ratio for exhibiting SARS-CoV-2 symptoms. Intensified testing and isolation of cases, identification of both asymptomatic and symptomatic individuals and additional care of those with co-morbidities and risk behaviours will all be collectively important for disease containment in India. Reasons for differentials in testing between men and women remain an important area for in-depth study. The increased deployment of vaccines is likely to impact the trajectory of COVID-19 in the coming time, and therefore our data will serve as a comparative resource as India experiences the second wave of infection in light of newer variants that are likely to accelerate disease spread.
Identifiants
pubmed: 34062097
doi: 10.1098/rsob.200288
pmc: PMC8169211
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
200288Références
Alcohol Res. 2015;37(2):159-70
pubmed: 26695755
Trans R Soc Trop Med Hyg. 2021 Jan 7;115(1):6-8
pubmed: 33045049
EClinicalMedicine. 2021 Feb;32:100717
pubmed: 33521608
BMJ Open. 2019 Aug 7;9(8):e026850
pubmed: 31391189
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
EClinicalMedicine. 2020 Aug;25:100501
pubmed: 32835187
J Glob Health. 2020 Dec;10(2):0203102
pubmed: 33335722
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):61-69
pubmed: 32773414
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Lancet Glob Health. 2021 Mar;9(3):e257-e266
pubmed: 33515512
Front Immunol. 2020 Aug 28;11:2147
pubmed: 32983176
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Br J Ophthalmol. 2020 Feb;104(2):220-224
pubmed: 31221669
Sci Rep. 2020 Aug 19;10(1):14004
pubmed: 32814791
Front Genet. 2020 Jul 28;11:854
pubmed: 32849833
EClinicalMedicine. 2020 Jul 04;24:100448
pubmed: 32766546
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Science. 2020 Nov 6;370(6517):691-697
pubmed: 33154136
Tob Induc Dis. 2020 Jul 03;18:58
pubmed: 32641924
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Assoc Physicians India. 2020 Jun;68(6):13-19
pubmed: 32610873
Am J Trop Med Hyg. 2020 Jul;103(1):28-30
pubmed: 32383431
SN Compr Clin Med. 2020 Jun 25;:1-8
pubmed: 32838147
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Lancet Public Health. 2020 May;5(5):e259
pubmed: 32277874
Crit Care. 2020 Mar 27;24(1):119
pubmed: 32220236
Med Hypotheses. 2020 Nov;144:109896
pubmed: 32585464
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452
pubmed: 32780793
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
J Med Virol. 2021 Jan;93(1):257-261
pubmed: 32603481
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60
pubmed: 32952144
Indian J Med Res. 2021 Jan & Feb;153(1 & 2):115-125
pubmed: 33818468
Indian J Med Res. 2020 May;151(5):490-492
pubmed: 32611918